Kura Oncology to Participate in Upcoming Investor Conferences
Rhea-AI Summary
SAN DIEGO, March 1, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, a clinical-stage biopharmaceutical company focused on precision cancer medicines, announced that CEO Troy Wilson will participate in several investor conferences. Key events include:
- A “Leukemia Corporate Panel” at the Cowen Health Care Conference in Boston on March 8, 2023, at 12:50 p.m. ET.
- A fireside chat at the Cowen Health Care Conference on the same day at 2:50 p.m. ET.
- A fireside chat at the Barclays Global Healthcare Conference in Miami on March 14, 2023, at 2:35 p.m. ET.
Live webcasts will be available on Kura's website, with archived replays post-event.
Positive
- None.
Negative
- None.
News Market Reaction – KURA
In the trading session that priced this news, KURA gained 0.25%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, March 01, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in the following events at upcoming investor conferences:
- A “Leukemia Corporate Panel” discussion at the Cowen Health Care Conference in Boston at 12:50 p.m. ET / 9:50 a.m. PT on March 8, 2023;
- A fireside chat at the Cowen Health Care Conference at 2:50 p.m. ET / 11:50 a.m. PT on March 8, 2023; and
- A fireside chat at the Barclays Global Healthcare Conference in Miami at 2:35 p.m. ET / 11:35 a.m. PT on March 14, 2023.
Live audio webcasts will be available in the Investors section of Kura’s website at www.kuraoncology.com, with archived replays available following the events.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined AML patients with high unmet need. Ziftomenib is currently enrolling patients in a Phase 2 registration-directed trial (KOMET-001) in NPM1-mutant relapsed or refractory AML. Kura is preparing to initiate multiple Phase 1 trials to evaluate ziftomenib in combination with current standards of care in earlier lines of therapy and across multiple patient populations, including NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial (KURRENT-HN) in combination with alpelisib for patients with PIK3CA-dependent HNSCC. Kura intends to evaluate KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial (FIT-001) as a monotherapy and in combination with other targeted therapies in adult patients with advanced solid tumors. For additional information, please visit Kura’s website at www.kuraoncology.com.
Contacts
Investors:
Pete De Spain
Senior Vice President, Investor Relations &
Corporate Communications
(858) 500-8803
pete@kuraoncology.com
Media:
Alexandra Weingarten
Senior Manager, Corporate Communications
(858) 500-8822
alexandra@kuraoncology.com
